KIT and gastrointestinal stromal tumor: In addition, the primary value of mutational status is in ensuring only patients with imatinib sensitive mutations (KIT mutations, and PDGFRA mutations other than D842V) receive imatinib–this group forms the vast majority (> 80%) of GIST patients.